NIH Funding Announcements

Syndicate content
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 45 min 7 sec ago

T2 Translational Research on Aging: Small Business Innovation Awards (R43/R44 Clinical Trial Optional)

Tue, 11/28/2017 - 12:20
Funding Opportunity PAR-18-184 from the NIH Guide for Grants and Contracts. The involvement of small businesses in translational aging research could hasten the pace at which scientific advances are transformed into commercial products to improve or maintain the health and functional independence of older adults. Therefore, this funding opportunity announcement (FOA) is intended to support innovative research conducted by small businesses through the SBIR program to advance the availability of novel devices, products, health care practices and programs with the potential for commercial success and the likelihood to benefit the lives of older adults.
Categories: NIH-Funding

T1 Translational Research on Aging: Small Business Innovation Awards (R43/R44 Clinical Trial Optional)

Tue, 11/28/2017 - 12:13
Funding Opportunity PAR-18-183 from the NIH Guide for Grants and Contracts. The involvement of small businesses in translational aging research could substantially hasten the pace at which scientific advances are transformed into commercial products to improve or maintain the health and functional independence of older adults. Therefore, this funding opportunity announcement (FOA) is intended to encourage a greater involvement by small businesses through the SBIR mechanism in transforming scientific advances in aging research into novel devices, products, health care practices and programs that will benefit the lives of older adults.
Categories: NIH-Funding

Development and/or Validation of Devices or Electronic Systems to Monitor or Enhance Mind and Body Interventions (R41/R42 Clinical Trial Optional)

Tue, 11/28/2017 - 12:09
Funding Opportunity PAS-18-121 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that will develop and/or validate devices or electronic systems that can: 1) monitor biologically- or behaviorally-based processes applicable to mind and body interventions or 2) be used to assist in optimizing the practice or increasing the efficacy of mind and body interventions. The applications should: 1) lead to the development of new technologies, 2) adapt existing innovative technologies, devices and/or electronic systems, 3) repurpose existing devices and electronic systems, or 4) conduct testing of single or combined components of an integrated, long term, automated, wearable monitoring, stimulation device or electronic system in order to monitor or enhance the mechanistic processes or functional outcomes of mind and body interventions. For the purposes of this FOA, mind and body interventions are defined as non-pharmacological approaches that include mind/brain focused interventions (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), or combined mind and body meditative movement approaches (e.g., yoga, tai-chi, qigong).
Categories: NIH-Funding

Development and/or Validation of Devices or Electronic Systems to Monitor or Enhance Mind and Body Interventions (R43/R44 Clinical Trial Optional)

Tue, 11/28/2017 - 12:06
Funding Opportunity PAS-18-120 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that will develop and/or validate devices or electronic systems that can: 1) monitor biologically- or behaviorally-based processes applicable to mind and body interventions or 2) be used to assist in optimizing the practice or increasing the efficacy of mind and body interventions. The applications should: 1) lead to the development of new technologies, 2) adapt existing innovative technologies, devices and/or electronic systems, 3) repurpose existing devices and electronic systems, or 4) conduct testing of single or combined components of an integrated, long term, automated, wearable monitoring, stimulation device or electronic system in order to monitor or enhance the mechanistic processes or functional outcomes of mind and body interventions. For the purposes of this FOA, mind and body interventions are defined as non-pharmacological approaches that include mind/brain focused interventions (e.g., meditation, hypnosis), body-based approaches (e.g., acupuncture, massage, spinal manipulation/mobilization), or combined mind and body meditative movement approaches (e.g., yoga, tai-chi, qigong).
Categories: NIH-Funding

Evaluating the NIDA Standardized Research E-Cigarette in Risk Reduction and Related Studies (U01 Clinical Trial Optional)

Tue, 11/28/2017 - 12:03
Funding Opportunity PAR-18-220 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate research evaluating electronic cigarettes (e-cigarettes, electronic nicotine delivery systems, ENDS) as a potential means of reducing the risks associated with combustible tobacco use. This goal will be achieved by funding clinical studies that use the newly-developed NIDA Standard Research E-cigarette (SREC) to examine potential risks and benefits associated with e-cigarette use in current tobacco smokers. Ultimately, this FOA aims to evaluate whether e-cigarettes can reduce the risks associated with combustible tobacco use and to establish the NIDA SREC as a standard to which other e-cigarettes can be compared. Studies submitted to this FOA should examine the effects of the SREC on multiple behavioral and health biomarkers in current tobacco smokers and may include examination of whether e-cigarettes can reduce the negative health impacts of conventional tobacco use, and / or examine their effects on craving and dependence. Funding will be contingent upon the FDA Center for Tobacco Products (CTP) determination that the studies fall under their regulatory jurisdiction. Furthermore, funding will require that CTP accepts the use of the NIDA SREC as an Investigational Tobacco Product (ITP) in the proposed study, or determines that an ITP is not required. Studies funded by this FOA are expected to rapidly increase understanding of whether e-cigarettes reduce the risks associated with tobacco use. Additionally, these studies may provide significant data to inform e-cigarette public health policy decision-making.
Categories: NIH-Funding

Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01 Clinical Trial Optional)

Tue, 11/28/2017 - 12:00
Funding Opportunity PAR-18-215 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.
Categories: NIH-Funding

Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21 Clinical Trial Optional)

Tue, 11/28/2017 - 11:58
Funding Opportunity PAR-18-214 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.
Categories: NIH-Funding

Wearable Alcohol Biosensors (R43/R44 Clinical Trial Optional)

Tue, 11/28/2017 - 11:55
Funding Opportunity PAR-18-204 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to encourage Small Business Innovation Research (SBIR) applications from eligible small business concerns proposing to design and produce a non-invasive, discreet, wearable device to monitor blood alcohol levels in real time. Methods that quantify alcohol in blood or interstitial fluid as opposed to detection of alcohol that has exuded through the skin are of particular interest.
Categories: NIH-Funding

NIDDK Exploratory Clinical Trials for Small Business (R44 Clinical Trial Required)

Tue, 11/28/2017 - 11:54
Funding Opportunity PAR-18-108 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies.
Categories: NIH-Funding

Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21 Clinical Trial Optional)

Tue, 11/28/2017 - 11:44
Funding Opportunity PAR-18-024 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research, such as: psychological science (e.g., social, developmental); affective and cognitive neuroscience; judgment and decision-making; consumer behavior and marketing; organizational behavior; sociology, cultural anthropology; behavioral economics; linguistics; and political science.
Categories: NIH-Funding

Tobacco Use and HIV in Low and Middle Income Countries (R01 Clinical Trial Optional)

Tue, 11/28/2017 - 11:42
Funding Opportunity PAR-18-023 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.
Categories: NIH-Funding

Revision: NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research

Tue, 11/28/2017 - 11:03
Notice NOT-OD-18-014 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Notice of Expiration of PAR-16-396 "NICHD Laboratory of Developmental Biology (R24)"

Tue, 11/28/2017 - 10:20
Notice NOT-HD-17-031 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Tobacco Use and HIV in Low and Middle Income Countries (R21 Clinical Trial Optional)

Tue, 11/28/2017 - 09:57
Funding Opportunity PAR-18-022 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.
Categories: NIH-Funding

Notice of Extension of the Response Date for NOT-OD-18-007 "Request for Information (RFI) on Enhancing Utilization of the NIH Clinical Center

Tue, 11/28/2017 - 09:52
Notice NOT-OD-18-016 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

Collaboratory on Research Definitions for Cognitive Reserve and Resilience to Alzheimer's Disease (R24 - Clinical Trial Not Allowed)

Tue, 11/28/2017 - 03:30
Funding Opportunity RFA-AG-18-024 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to provide infrastructure support to advance development of operational definitions and approaches for the study of the concepts of cognitive reserve and resilience to Alzheimers disease and related dementias (ADRD) and age-related cognitive decline. The infrastructure support will facilitate a collaborative research network through meetings, conferences, small-scale pilots, and dissemination activities to foster development and champion use of state-of-the-art definitions, uniform nomenclature, and validated approaches that will be key to the advancement of research on maintenance of brain and cognitive health and treatment and/or prevention of ADRD.
Categories: NIH-Funding

Innovative Research in HIV in Kidney, Urology, and Hematology (R01 Clinical Trial Optional)

Tue, 11/28/2017 - 03:13
Funding Opportunity RFA-DK-17-037 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for innovative research projects examining the basic and clinical aspects of HIV infection, treatment, and long-term sequelae as they relate to the mission of the Division of Kidney, Urologic and Hematologic Diseases within NIDDK (KUH/NIDDK).
Categories: NIH-Funding

NHLBI Career Transition Award for Intramural Fellows (K22) (Clinical Trials Required)

Tue, 11/28/2017 - 02:57
Funding Opportunity PAR-18-424 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Career Transition Award (K22) program is to provide highly qualified postdoctoral fellows in the NHLBI Division of Intramural Research the opportunity to transition their research programs as new investigators to extramural institutions. To achieve these objectives, the NHLBI Career Transition Award will support two phases of research: a mentored intramural phase (up to two years) and an extramural phase (three years), for a total of five years of combined support. Transition from the intramural phase of support to the extramural phase is not automatic. Approval of the transition will be based on the success of the awardee's research program during the mentored phase as determined by an NHLBI progress review, which will include an evaluation of a research plan to be carried out at the extramural institution. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA #).
Categories: NIH-Funding